Details of the Drug
General Information of Drug (ID: DMIQOXH)
Drug Name |
Apigenin-7-O-beta-D-glucuronide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
29741-09-1; Apigenin-7-glucuronide; Apigenin 7-O-b-glucuronide; Apigenin 7-glucuronide; apigenin-7-o-glucuronide; UNII-2CQ5KB3CH0; 2CQ5KB3CH0; CHEMBL254213; Scutellarin A; Apigenin 7-O-glucuronide; Apigenin 7-beta-glucuronide; apigenin-7-O-beta-D-glucuronide; Apigenin 7-O-beta-D-glucuronide; Apigenin-7-O-beta-D-glucuronoside; Apigenin 7-O-beta-D-glucuronopyranoside; AC1NSY61; MEGxp0_000795; SCHEMBL2400851; ACon1_001025; DTXSID10183893; MolPort-001-740-947; apigenin-7-O-betaD-glucuronic acid; HY-N1454; Apigenin 7-O-.beta.-D-glucur
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 446.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 6 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 11 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||